Latest Administration News

Imugene Limited has launched a $37.5 million equity raising through a Placement and Share Purchase Plan, offering new shares and options to fund its pivotal azer-cel clinical program. The raise includes attaching and piggyback options, subject to shareholder approval, aiming to bolster the company’s immuno-oncology pipeline.

Alliance Nickel has strengthened its financial position with an additional A$1.2 million unsecured loan and extended existing facilities, while reaffirming the commercial viability of its NiWest Nickel-Cobalt Project through a comprehensive Definitive Feasibility Study.

Prescient Therapeutics has initiated its first US clinical site for the PTX-100 Phase 2a trial targeting Cutaneous T-Cell Lymphoma, marking a key milestone in expanding patient recruitment beyond Australia.

Imagion Biosystems has received encouraging feedback from the FDA on its MagSense HER2 breast cancer imaging program, clearing the path for a Phase 2 clinical trial and fast-tracking manufacturing.

Prescient Therapeutics has extended its Share Purchase Plan closing date to 22 July 2025, aiming to raise up to A$7 million to advance its targeted cancer therapy PTX-100 through Phase 2 clinical trials.

HUB24 Limited has reported a record $19.8 billion in net inflows for FY25, driven by strong platform growth and significant migrations from Equity Trustees. The company also launched an innovative high net worth solution, reinforcing its market leadership.

Imugene Limited reports promising Phase 1b trial results for azer-cel, an off-the-shelf CAR T therapy, showing a 75% overall response rate in relapsed diffuse large B-cell lymphoma patients. The company plans to engage the FDA later this year to discuss pivotal trial design.

Energy Transition Minerals has submitted a binding offer to acquire the Penouta Mine in Spain, a critical asset for Europe’s supply of tantalum and niobium. The outcome hinges on regulatory approvals and competitive bidding.

Indiana Resources appoints seasoned mining executive Matthew Bowles as Managing Director to spearhead expansion at its Minos Gold Project, while promoting John Fitzgerald to COO amid a strong cash position.

Pacific Edge reports steady demand for its Cxbladder cancer diagnostic tests despite losing Medicare coverage and transitioning US customers to a new test. The company is advancing clinical evidence and a $21 million capital raise to support growth and regain coverage.

Queste Communications reported a significant $3 million cash inflow in June 2025, driven by a royalty termination payment from its controlled entity, Orion Equities Limited, strengthening its liquidity position.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing of Elate Ocular, a promising treatment for moderate to severe dry eye disease, pending additional financing.